Department of Internal Medicine, Division of Epidemiology, Biostatistics and Preventive Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, 87131, USA.
Department of Medicine, Division of General Internal Medicine, School of Medicine, University of Pittsburgh, 200 Meyran Ave, Suite 300, Pittsburgh, PA, 15213, USA.
Addict Sci Clin Pract. 2023 Jan 27;18(1):6. doi: 10.1186/s13722-023-00362-5.
BACKGROUND: Identifying patients in primary care services with opioid use disorder and co-occurring mental health disorders is critical to providing treatment. Objectives of this study were to (1) assess the feasibility of recruiting people to screen in-person for opioid use disorder and co-occurring mental health disorders (depression and/or post-traumatic stress disorder) in primary care clinic waiting rooms in preparation for a randomized controlled trial, and (2) compare results of detecting these disorders by universal in-person screening compared to electronic health record (EHR) diagnoses. METHODS: This cross-sectional feasibility and pilot study recruited participants from four primary care clinics, two rural and two urban, from three health care organizations in New Mexico. Inclusion criteria were adults (≥ 18 years), attending one of the four clinics as a patient, and who spoke English or Spanish. Exclusion criteria were people attending the clinic for a non-primary care visit (e.g., dental, prescription pick up, social support). The main outcomes and measures were (1) recruitment feasibility which was assessed by frequencies and proportions of people approached and consented for in-person screening, and (2) relative differences of detecting opioid use disorder and co-occurring mental health disorders in waiting rooms relative to aggregate EHR data from each clinic, measured by prevalence and prevalence ratios. RESULTS: Over two-weeks, 1478 potential participants were approached and 1145 were consented and screened (77.5% of patients approached). Probable opioid use disorder and co-occurring mental health disorders were identified in 2.4% of those screened compared to 0.8% in EHR. Similarly, universal screening relative to EHR identified higher proportions of probable opioid use disorder (4.5% vs. 3.4%), depression (17.5% vs. 12.7%) and post-traumatic stress disorder (19.0% vs. 3.6%). CONCLUSIONS: Universal screening for opioid use disorder, depression, and post-traumatic stress disorder was feasible, and identified three times as many patients with these co-occurring disorders compared to EHR. Higher proportions of each condition were also identified, especially post-traumatic stress disorder. Results support that there are likely gaps in identification of these disorders in primary care services and demonstrate the need to better address the persistent public health problem of these co-occurring disorders.
背景:在初级保健服务中识别出患有阿片类药物使用障碍和并发精神健康障碍(抑郁和/或创伤后应激障碍)的患者对于提供治疗至关重要。本研究的目的是:(1)评估在初级保健诊所候诊室中对阿片类药物使用障碍和并发精神健康障碍(抑郁和/或创伤后应激障碍)进行现场筛查以准备进行随机对照试验的可行性,以及(2)比较通过普遍现场筛查与电子健康记录(EHR)诊断来检测这些疾病的结果。
方法:这项横断面可行性和试点研究从新墨西哥州三个医疗保健组织的四个初级保健诊所招募参与者,其中两个位于农村,两个位于城市。纳入标准为成年人(≥18 岁),作为患者之一到四个诊所中的一个就诊,并且会讲英语或西班牙语。排除标准为来诊所就诊的人是非初级保健就诊(例如,牙科、取药、社会支持)。主要结局和措施为:(1)通过接触和同意进行现场筛查的人数和比例来评估招募的可行性,以及(2)通过每个诊所的综合 EHR 数据检测到的阿片类药物使用障碍和并发精神健康障碍的相对差异,通过患病率和患病率比来衡量。
结果:在两周内,接触了 1478 名潜在参与者,其中 1145 名同意并接受了筛查(接受筛查的患者占 77.5%)。与 EHR 相比,在接受筛查的患者中发现了 2.4%的可能患有阿片类药物使用障碍和并发精神健康障碍,而 EHR 中为 0.8%。同样,与 EHR 相比,普遍筛查发现可能患有阿片类药物使用障碍(4.5%比 3.4%)、抑郁(17.5%比 12.7%)和创伤后应激障碍(19.0%比 3.6%)的比例更高。
结论:普遍筛查阿片类药物使用障碍、抑郁和创伤后应激障碍是可行的,与 EHR 相比,它识别出了三倍以上同时患有这些共病的患者。每种疾病的比例也更高,尤其是创伤后应激障碍。结果表明,在初级保健服务中,这些疾病的识别可能存在差距,并表明需要更好地解决这些共病的持续公共卫生问题。
Addict Sci Clin Pract. 2023-1-27
Cochrane Database Syst Rev. 2015-1-20
Cochrane Database Syst Rev. 2016-4-4
Cochrane Database Syst Rev. 2020-7-1
Cochrane Database Syst Rev. 2015-9-18
Cochrane Database Syst Rev. 2015-3-5
Cochrane Database Syst Rev. 2016-3-12
Cochrane Database Syst Rev. 2017-1-24
J Trauma Stress. 2024-12
JAMA Netw Open. 2021-5-3
MMWR Morb Mortal Wkly Rep. 2020-8-14
J Prim Care Community Health. 2020
Subst Abuse Treat Prev Policy. 2020-3-16